Patents Assigned to Zymeworks Inc.
-
Patent number: 9914785Abstract: The present invention provides heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the CH1 and/or CL domains, amino acid modifications in the VH and/or VL domains or a combination thereof. The modified amino acid residues are part of the interface between the light chain and heavy chain and are modified in order to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a mammalian cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer preferentially pairs with the second light chain rather than first.Type: GrantFiled: November 27, 2013Date of Patent: March 13, 2018Assignee: ZYMEWORKS INC.Inventors: Adam Louis Corper, Dunja Urosev, Stacey A. L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
-
Patent number: 9879086Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.Type: GrantFiled: September 17, 2015Date of Patent: January 30, 2018Assignee: ZYMEWORKS INC.Inventors: Geoffrey C. Winters, James R. Rich, Graham Albert Edwin Garnett, Alexander Laurence Mandel, Tom Han Hsiao Hsieh, Elyse Marie Josée Bourque, Stuart Daniel Barnscher
-
Patent number: 9771573Abstract: Provided is a method of quantitatively determining the ability of individual IgG heavy chains to selectively pair with a particular IgG light chain when the heavy chains and two unique light chains are co-expressed. The method provides results with reasonable throughput and is robust and accurate. The co-expressed heavy and light chains do not need to be isolated and purified which enables more efficient screening.Type: GrantFiled: October 3, 2013Date of Patent: September 26, 2017Assignees: ZYMEWORKS INC., NATIONAL RESEARCH COUNCIL OF CANADAInventors: Anders Ohrn, Adam Louis Corper, Gordon Yiu Kon Ng, Antonios Samiotakis, Yang-Chieh Chou, Jason Baardsnes, Maureen O'Connor-McCourt
-
Publication number: 20170246310Abstract: VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.Type: ApplicationFiled: December 29, 2014Publication date: August 31, 2017Applicants: ZYMEWORKS INC., VAR2 PHARMACEUTICALS APSInventors: James R. RICH, John BABCOOK, Ali EL-SALANTI, Mads DAUGAARD, Madeleine DAHLBACK, Bradley J. HEDBERG, Geoffrey C. WINTERS, Alexander L. MANDEL, Elyse Marie Josée BOURQUE, Tom Han Hsiao HSIEH
-
Patent number: 9732155Abstract: Disclosed are the atomic coordinates of compositions comprising Fc heterodimer proteins in crystalline form derived from high resolution x-ray diffraction. Further disclosed are systems and methods for using all or a portion of these atomic coordinates to identify and design improved Fc heterodimer proteins. Further disclosed are compositions comprising a mixture of (i) a solubilized Fc heterodimer protein and (ii) a mother liquor solution. The mother liquor solution comprises between 2% and 10% (v/v) ethylene glycol, between 10% and 25% (w/v) polyethylene glycol having an average molecular weight of between 2000 Daltons and 10000 Daltons, and between 0.05 M and 0.40 M ammonium iodide. Further disclosed are systems and methods of identifying a mutation which promotes heterodimeric Fc chain pair formation in which structure based modeling is performed to identify a candidate mutation to an Fc chain using all or a portion of the disclosed three-dimensional atomic coordinates.Type: GrantFiled: October 31, 2013Date of Patent: August 15, 2017Assignee: ZYMEWORKS INC.Inventors: Thomas Spreter Von Kreudenstein, Surjit Bhimarao Dixit, Paula Irene Lario, Eric Escobar-Cabrera, Martin J. Boulanger, Michael D. L. Suits
-
Publication number: 20170204199Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: ApplicationFiled: May 29, 2015Publication date: July 20, 2017Applicant: ZYMEWORKS INC.Inventors: Mario Sanches, Thomas Spreter Von Kreudenstein, Dunja Urosev, Stacey A. L. Tom-Yew, Adam Louis Corper, Igor Edmondo Paolo D'Angelo, Yang-Chieh Chou, Surjit Bhimarao Dixit
-
Patent number: 9697305Abstract: Systems and methods for evaluating thermodynamics of atomic changes in a polymer include using a first portion of a refined derived set of three-dimensional coordinates for a derivation of the polymer, which incorporates the atomic change under study, to compute a first effective atomistic Hessian. A second effective atomistic Hessian is computed using a second portion of a refined native set of three-dimensional coordinates for the native polymer. Atoms in the first and second portions are identical. A thermodynamic property of the first portion is determined using the refined derived set of three-dimensional coordinates and the first effective atomistic Hessian. A thermodynamic property of the second portion of the native polymer is determined using the refined native set of three-dimensional coordinates and the second effective atomistic Hessian. The effect of the atomic changes is quantified by taking the difference between the calculated thermodynamic properties of the first and second portions.Type: GrantFiled: March 13, 2014Date of Patent: July 4, 2017Assignee: ZYMEWORKS INC.Inventors: Gregory Lakatos, James Liam McWhirter
-
Patent number: 9574010Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: GrantFiled: November 2, 2012Date of Patent: February 21, 2017Assignee: Zymeworks Inc.Inventors: Thomas Spreter Von Kreudenstein, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Paula Irene Lario, David Kai Yuen Poon
-
Patent number: 9562109Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: GrantFiled: November 4, 2011Date of Patent: February 7, 2017Assignee: Zymeworks Inc.Inventors: Thomas Spreter Von Kreudenstein, Eric Escobar Cabrera, Surjit Bhimarao Dixit, Paula Irene Lario, David Kai Yuen Poon
-
Publication number: 20170029490Abstract: Sulfonamide-containing linkage systems for release of payload compounds from an attached targeting moiety in drug conjugates. The conjugates have the formula of [(P)-(L)]m-(T), wherein (P) is a payload compound, (L) is a linker, (T) is a targeting moiety and m is an integer from 1- to 10. Also provided are pharmaceutical compositions comprising such conjugates and there use in treating cancer.Type: ApplicationFiled: December 29, 2014Publication date: February 2, 2017Applicant: ZYMEWORKS INC.Inventors: Geoffrey C. WINTERS, Alexander L. MANDEL, Elyse Marie Josée BOURQUE, James R. RICH, Tom Han Hsiao HSIEH
-
Patent number: 9522876Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4 and R5 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having structure (I).Type: GrantFiled: March 14, 2014Date of Patent: December 20, 2016Assignee: ZYMEWORKS INC.Inventors: Geoffrey C. Winters, Alexander L. Mandel, Bradley J. Hedberg, John Babcook, James R. Rich, Tom Han Hsiao Hsieh, Elyse Marie Josée Bourque
-
Patent number: 9499634Abstract: The present invention provides a process and methods for producing asymmetric antibodies in a mammalian expression system. The asymmetric antibodies are transiently or stably expressed and in cells that stably express the asymmetric antibody, following a rapid 2-step process of stable pool to clone, a highly pure asymmetric antibody expressing clone can be identified at a success frequency that permits for screening of tens of clones rather than thousands. The asymmetric antibodies are produced at a high titre and with a high level of purity with no contaminating homodimer antibodies following protein A purification with a step yield of near 100%. Typical downstream purification processes employ standard hydrophobic interaction chromatography (HIC) and/or cation exchange (CEX) resins and the antibody is stable within a wide dynamic range of buffer pH (4-8) and within the requirements for manufacturing antibodies for pre-clinical and clinical applications.Type: GrantFiled: June 25, 2013Date of Patent: November 22, 2016Assignee: Zymeworks Inc.Inventors: Surjit Bhimarao Dixit, Gordon Yiu Kon Ng, Thomas Spreter Von Kreudenstein
-
Patent number: 9499605Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.Type: GrantFiled: March 2, 2012Date of Patent: November 22, 2016Assignee: Zymeworks Inc.Inventors: Surjit Bhimarao Dixit, Igor Edmundo Paolo D'Angelo, David Kai Yuen Poon
-
Publication number: 20160326249Abstract: Antigen-binding constructs, e.g., antibodies, which bind CD3 and CD 19 and methods of use are disclosed.Type: ApplicationFiled: January 15, 2015Publication date: November 10, 2016Applicant: Zymeworks Inc.Inventors: Gordon Yiu Kon Ng, Thomas Spreter von Kreudenstein, Leonard G. Presta
-
Patent number: 9404928Abstract: The invention provides methods and systems of determining biopolymer profiles and correlations between structural units (residues) of a biopolymer based on sampling of the conformational space available to the molecule. The correlations between these structural units can further be used to find networks within a biopolymer such as the coupled residue networks in a protein. The invention also provides for designing and engineering biopolymers including polypeptides, nucleic acids and carbohydrates using the information derived from the conformation clustering and subsequent methods described herein.Type: GrantFiled: February 5, 2009Date of Patent: August 2, 2016Assignee: ZYMEWORKS INC.Inventors: Paula I. Lario, Johannes Mullegger, Anne-Marie Baribeau, Surjit B. Dixit, Tomas Rodinger, Powell Patrick Cheng Tan
-
Patent number: 9388231Abstract: Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.Type: GrantFiled: July 13, 2013Date of Patent: July 12, 2016Assignee: Zymeworks Inc.Inventors: Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, Mario Sanches, Gordon Yiu Kon Ng
-
Publication number: 20160188789Abstract: Systems and methods for evaluating a polymer make use of a workflow request identifying input data and a workflow instance. The workflow instance comprises a plurality of actors, each having one or more input and output ports. The workflow instance defines an acyclic directed graph comprising nodes and edges. Each node is an actor in the plurality of actors and each edge corresponds to at least one of (i) an input port of an actor in the plurality of actors and (ii) an output port of an actor in the plurality of actors. Graph parsing produces an ordered list of job requests. Each job request corresponds to an actor in the plurality of actors. An actor in the plurality of actors is executed in an order specified by the ordered list and contributes an output to another actor in the plurality of actors that is specified by the graph.Type: ApplicationFiled: July 14, 2014Publication date: June 30, 2016Applicant: ZYMEWORKS INC.Inventors: Kamil KISIEL, Siddharth SRINIVASAN
-
Patent number: 9296815Abstract: Rationally designed antibodies and polypeptides that comprise multiple Fc region amino acid substitutions that synergistically provide enhanced selectivity and binding affinity to a target Fc receptor are provided. The polypeptides are mutated at multiple positions to make them more effective when incorporated in antibody therapeutics than those having wild-type Fc components.Type: GrantFiled: March 28, 2011Date of Patent: March 29, 2016Assignee: Zymeworks Inc.Inventors: Igor D'Angelo, Dustin Bleile, Stacey A. L. Tom-Yew, Eric Escobar-Cabrera, Paula I. Lario, Anders Ohrn, David K. Y. Poon, Surjit B. Dixit
-
Publication number: 20160083480Abstract: Described herein are isolated bi-specific antigen binding constructs, e.g., antibodies. The bi-specific antigen binding constructs include two antigen binding polypeptide constructs, e.g., a Fab and an scFv. The first antigen-binding polypeptide construct monovalently and specifically binds to extracellular domain 4 (ECD4) of HER2 (human epidermal growth factor receptor 2); the second antigen-binding polypeptide construct monovalently and specifically binds to an extracellular domain (ECD) of HER3 (human epidermal growth factor receptor 3). One antigen binding polypeptide construct is a Fab format and the other antigen binding polypeptide construct is an scFv format. The bi-specific antigen binding constructs includes an Fc having two Fc polypeptides each having a CH3 domain for dimerization. Each Fc polypeptide is linked to the C-terminus of one of the antigen binding polypeptide constructs with or without a linker.Type: ApplicationFiled: May 8, 2014Publication date: March 24, 2016Applicant: ZYMEWORKS INC.Inventors: Gordon Yiu Kon NG, Peter Wing Yiu Chan, Grant Raymond Wickman
-
Patent number: 9165052Abstract: A new density based clustering method for clustering data points in multidimensional space is described. Each point has a neighborhood consisting of all points that are within a preset cutoff radius or distance. Each point is assigned a density measure based on the number of points in its neighborhood. Any point that has a higher density than any of its neighboring points is the center of a cluster and is assigned a unique cluster ID. Every other point follows a path through the graph of neighboring points such that density is increasing as fast as possible until a cluster center is reached. The algorithm's performance is demonstrated on a one-dimensional, two-dimensional, and 18-dimensional dataset.Type: GrantFiled: November 23, 2010Date of Patent: October 20, 2015Assignee: ZYMEWORKS INC.Inventors: Tomas Rodinger, Paula L. Lario